您好,欢迎来到上海士研管理咨询有限公司
产业峰会 演讲局 专家智库服务 峰会活动服务 整合营销服务
  • 产业峰会:
    以专业团队对产业和市场客观详实地调研为前提,拥有战略性、系统性、全球性的基因,汇集了领导者关注的热点话题与领袖代表,为您提供“一站式”的对话、分享、社交平台!
  • 演讲局:
    致力于为全球企业和机构提供主题演讲家、高管大师班、董事会顾问,每项服务都提供了一种更深入、更具互动性的体验,尤其是针对较小的精选受众和关键个人。我们拥有最具影响力的商业领袖和顶级专家的资源,他们是各自领域的最杰出的代表。我们的团队由经验丰富的演讲和活动经理组成,我们注重建立长期而深入的伙伴关系。
  • 专家智库服务:
    中国领先的行业专家知识信息服务供应商,为需要专业洞见的商业决策者匹配具有一手经验的行业专家,助力他们以更加明确的目标和坚定的信心做出决策。我们有60万余名专家顾问遍布二十多个行业,而且每天还在增加!
  • 峰会活动服务:
    致力于成为全球最专业的产业峰会活动提供商,为企业和机构的产业性峰会活动提供一站式专业服务,包括调研策划、定制邀请、营销推广、运营组织、项目管理、直播与数字化会议等,每项服务都由经验丰富的专业团队匹配长期沉淀的产业资源予以卓越执行,我们注重建立长期而深入的伙伴关系。
  • 整合营销服务:
    致力于成为全球领先的2B营销服务机构,聚焦产业高端活动、内容、渠道的建设与沉淀,为客户提供一站式整合营销解决方案,助力企业线上线下获客与品牌筑造。我们深信专业团队匹配产业资源带来卓越执行,我们注重建立长期而深入的伙伴关系。
嘉宾信息
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位: 首席投资官
所属公司: 先声药业
个人简介:
周高波,先声药业首席投资官,负责公司创新药投资和合作业务的拓展、新投资平台建设以及战略规划与实践。加入先声药业之前,周高波先生在麦肯锡公司担任全球董事合伙人和大中华区医疗咨询联席负责人,拥有十五年医疗行业管理咨询经验,致力于为领先的制药、生物科技、医疗器械、生命科学投资公司提供战略和管理咨询服务,深入探索中国医改和创新环境下的企业战略、创新商业模式、数字化转型、投资合作,并组建了行业内最大的医疗领域管理咨询团队。此前,他在人类基因组科学公司(HGSI)从事抗体和融合蛋白药物的研发工作。周高波先生拥有杜克大学商学院的工商管理硕士学位,马里兰大学生物化学硕士学位和复旦大学的遗传学本科学位。 Mr. Zhou Gaobo is the Chief Investment Officer of Simcere Pharmaceutical Group (2096.HK). He is in charge of the company's innovative drug investment and business development, establishment of new investment platforms, and investment strategy planning and practice.Prior to joining Simcere, Mr. Gaobo Zhou was a Partner at McKinsey & Company and co-leader of the Greater China Healthcare practice. He has fifteen years of experience in management consulting in the healthcare industry. He worked with leading pharmaceutical, biotechnology, medical device, and life science investment companies on a broad range of topics in the context of China’s Healthcare Reform and innovation, including strategy, business model innovation, digital transformation, and investment and partnership. He also built the largest healthcare management consulting team in the industry. Previously, he also worked at Human Genome Sciences (HGSI) in antibody and fusion protein drug development.
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位: 投资合伙人
所属公司: 启明创投
个人简介:
沈阳药科大学获得学士、中科院硕士、长江商学院EMBA 硕士。现任启明创投医疗健康投资合伙人。唐女士加入启明前,在晨兴创投工作13年,担任晨兴北京办公室总经理。在此期间,独立投资并在董事会层面管理超过20家早期生物医药公司。 其中大部分均已通过上市或并购途径成功退出,回报丰厚。加入晨兴之前,唐女士在葛兰素史克工作七年,其中五年做新药注册,两年做产品经理。在启明工作期间,投资项目包括神州细胞,义翘神州,加科思,科州,克睿基因,和其瑞等公司。 Amy earned her master's degree in Chinese Academy of Sciences and a bachelor's degree from Shen Yang Pharmaceutical University. Amy is also a graduate of EMBA course of Cheung Kong Graduate School of Business (CKGSB).Ms. Amy Tang is a Venture Partner at Qiming Venture Partners.Amy previously worked in Morningside Ventures for 13 years in charge of its Beijing office. Amy invested and managed dozens of early stage biotech portfolios during this period. Up till now, most of the investments have exited via IPOs or M&A with multiple returns.Prior to joining Morningside, Amy worked in GSK as a regulatory manager for five years and product manager for two years. In Qiming, Amy invested in several biotech companies including SinoCellTech, SinoBiological, Jacobio, KeChow, CureGenetics and HopeMedicine etc.
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位: 高级项目经理
所属公司: 上海(南翔)精准医学产业园
个人简介:
陈苗苗,现任高级项目经理,负责上海(南翔)精准医学产业园招商、项目引进、政策对接和融资服务等工作。2019年毕业后加入复旦大学宁波研究院,接触到的项目近800余家,落户服务项目20家,针对项目需求给出不同的解决方案,最终达到双赢的目标。从项目选址到最终项目入驻全部一手服务。 Mino, senior project manager, is responsible for investment promotion, project introduction, policy docking and financing services of Shanghai (Nanxiang) Precision Medicine Industrial Park. After graduation in 2019, I joined The Ningbo Research Institute of Fudan University. I came into contact with more than 800 projects and offered settlement service to 20 projects. I provided different solutions according to the needs of the projects and finally achieved a win-win goal. From project site selection to the final project settlement of all first-hand services.
发布时间: 2022 - 03 - 16
点击次数: 0
所属职位: 高级合伙人
所属公司: 鼎晖投资
个人简介:
柳丹博士现任鼎晖投资高级合伙人,负责健康医疗领域的投资,代表项目包括:成都先导(688222.SH)、天境生物(IMAB.O)、和铂医药-B(2142.HK)、九强生物·迈新生物(300406)、集萃药康、新格元生物、齐碳科技等。在加入鼎晖投资前,柳博士曾在Bain & Company从事大健康领域和大消费领域的管理咨询业务。期间,他服务并负责过多个大型跨国医药和器械企业的战略项目。柳丹博士在科研、商业、管理、咨询、投资等多领域拥有近二十年健康医疗行业相关经验。柳丹博士同时担任多个政府、行业协会理事和高级专家,及多个省市级科技和人才项目的审评专家。获评“投资界2021 F40中国青年投资人”、“2021年度最佳医疗大健康领域投资人物TOP 10”、“医疗健康投资卓悦榜40 Under 40.年度医疗健康投资人”、“未来医疗100强.年度青年投资人”。 Dr. Dan LIU is the Senior Partner at CDH Investments, in charge of Healthcare Investments of Venture and Growth Capital. Dr. LIU has led a series of life science investments, including HitGen (688222.SH)、I-Mab (IMAB.O)、Harbour BioMed (2142.HK)、Maxim Biotechnologies (300406), and currently sits on board of nearly 20 portfolio companies.Prior to joining CDH, Dr. LIU has successively worked at a number of multi-national corporations as management roles and extensive experience in domestic and cross-border healthcare industries. He was the former key professional of Asia Healthcare practice at Bain and Company.Dr. Liu is a seasoned scientist, consultant and investor with nearly 20 years of experience in Healthcare Sector.
微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务